Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07457918 · ClinicalTrials.gov registry record · Phase 3
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
A Phase 3 study, sponsored by Verrica Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 600
- Enrollment target
NCT07457918 is a Phase 3 study that is actively recruiting participants, run by Verrica Pharmaceuticals. The registered enrollment target is 600 participants.
The verdict
NCT07457918, a Phase 3 study, is actively recruiting participants, sponsored by Verrica Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 600 participants
- Enrollment target
Study Summary
People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are: * To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in Japan) by assessing concomitant medication use, and adverse events (AEs), including expected local skin reactions (LSRs). * To evaluate the efficacy of continued skin application of YCANTH (VP-102/TO-208) when applied to each common wart once every 21 days for a maximum of 4 additional treatments. Participants with eligible common warts present will receive YCANTH (VP-102/TO-208) with an interval of 21 (± 4) days between applications until there is a wart count of zero (ie, completed clearance has been achieved) or a maximum of 4 additional treatments. Participants with complete clearance will attend Observation Visits at intervals of 42 (± 4) days without treatment. Participants who develop a new wart after having a wart count of zero will resume Treatment Visits every 21 (± 4) days for a maximum of 4 additional treatments. All subjects will attend visits until the End-of-Study (EOS) Visit, which is on Day 378 (0/+ 8 days). If participants still have warts present after 4 additional treatments of YCANTH (VP-102/TO-208) the wart(s) will be discontinued from study and participants will be allowed to seek treatment but should be limited to destructive therapy such as cryosurgery and warts cannot be within 10 mm of any warts that receive(d) study drug treatment . The exact interval of Treatment Visits will be determined by evaluation of the treatment site, taking into account any ongoing local skin reactions (LSRs), which are defined as temporary application site: vesiculation, pain, pruritus, scabbing, erythema, discoloration, dryness, edema and erosion that is expected and consistent with historical treatment with YCANTH (VP-102/TO-208). Participants may receive treatme
Interventions
- COMBINATION_PRODUCT Cantharidin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2028-05-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07457918
The ClinicalTrials.gov registry entry for NCT07457918 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Verrica Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cantharidin is the first listed.
NCT07457918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07457918 about?
NCT07457918 is a clinical study titled "Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)". People who participated in either the COVE-2 or COVE-3 study for common warts, may be eligible to enroll into this Long Term Follow Up (LTFU) study COVE-4. The main question(s) to answer in this LTFU study are: * To assess the safety of YCANTH (also known as VP-102 in the United Sates or TO-208 in ...
What is the current status of trial NCT07457918?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 600 participants. The study started on 2026-03-11. Estimated completion is 2028-05-22.
What interventions are being tested in trial NCT07457918?
The interventions under investigation include: Cantharidin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT07457918?
This trial is sponsored by Verrica Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.